As March approaches, the FDA is expected to announce key decisions on the New Drug Applications for Reproxalap, Linerixibat, Kresladi, and LNTH-2501. For Kresladi, this marks a second bid for approval, while Reproxalap is making its third attempt. The path to FDA approval is often challenging for many drug candidates.
Meanwhile, approved therapies Sotyktu and Imcivree await decisions on label expansions, adding further regulatory catalysts to the month.
For comments and feedback contact: editorial@rttnews.com
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.